Filing Summary
Filing identity: The supplied Form 10-Q identifies the registrant as Neuralstem, Inc., not Palisade Bio, Inc. The report covers the quarter ended March 31, 2016 and was filed May 9, 2016.
Business Context and Reporting Period
Neuralstem is a clinical-stage biotechnology company developing central nervous system therapies based on NSI-189, a small-molecule compound, and NSI-566, a neural stem-cell therapy. The company had 32 full-time employees at March 31, 2016 and operated in the United States and China.
- NSI-189 Phase 2 major depressive disorder trial commenced in March 2016; the approximately 220-subject study was expected to begin enrolling in the second quarter of 2016, with results expected in the second half of 2017.
- Management announced a strategic refocusing on NSI-189 and plans to seek external funding or partnerships for the NSI-566 stem-cell programs.
- The interim financial statements are unaudited and prepared under U.S. GAAP.
Financial Performance and Position
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | $2,500 | $2,917 | Down $417 |
| Research and development expense | $3.066 million | $3.183 million | Down 4% |
| General and administrative expense | $3.171 million | $1.433 million | Up 121% |
| Total operating expenses | $6.236 million | $4.616 million | Up 35% |
| Operating loss | $6.234 million | $4.613 million | Worsened by $1.621 million |
| Net loss | $6.606 million | $5.053 million | Worsened by $1.553 million |
| Net loss per share | $0.07 | $0.06 | Loss increased |
| Cash used in operating activities | $3.488 million | $4.720 million | Use decreased by $1.232 million |
Revenue consisted primarily of intellectual-property licensing and related fees; the company generated no revenue from product sales. No meaningful operating margin existed because revenue was negligible relative to operating expenses.
- Cash and cash equivalents were $7.621 million at March 31, 2016, compared with $4.717 million at December 31, 2015.
- Short-term investments declined from $7.517 million at year-end 2015 to zero, primarily because certificates of deposit matured and were converted to cash.
- Total assets were $10.199 million; total liabilities were $10.368 million; stockholders’ deficit was $169,000.
- Debt consisted of approximately $7.235 million of aggregate principal outstanding. The secured loan bears a variable interest rate with a 10% floor, is collateralized by substantially all assets including intellectual property, and includes approximately $435,000 monthly principal and interest payments through March 2017 plus an approximately $2.8 million balloon payment in April 2017.
- Share-based compensation expense was $1.471 million, including approximately $407,000 related to accelerated vesting for the former chief executive officer.
Material Changes Versus the Prior Comparable Period
- General and administrative expense increased $1.737 million, primarily because of former CEO severance accruals and accelerated option vesting.
- Research and development expense decreased $117,000, reflecting lower preclinical and clinical costs partly offset by increased headcount and share-based compensation.
- Net loss increased 31% to $6.606 million from $5.053 million.
- Operating cash burn improved to $3.488 million from $4.720 million, while investing cash flow increased because $7.517 million of short-term investments matured.
- Financing cash flow changed from $5.892 million of inflows in Q1 2015 to $1.097 million of outflows in Q1 2016, primarily due to debt repayments and the absence of comparable equity and warrant proceeds.
- Common shares outstanding were approximately 92.044 million at March 31, 2016, compared with 92.006 million at December 31, 2015.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that the $7.6 million cash balance at March 31, 2016 was sufficient to fund operations only through June 2016 and that additional capital was required.
- On May 6, 2016, after the quarter-end, the company completed an offering of 20 million common shares and 20 million warrants, receiving $8.0 million gross and approximately $7.42 million net proceeds. Management stated that the financing extended expected funding through at least December 31, 2016. The warrants have a five-year term and a $0.40 exercise price.
- The company has incurred losses since inception, has not achieved profitability, and disclosed substantial doubt about its ability to continue as a going concern absent additional financing. The December 31, 2015 audit report also included a going-concern warning.
- Neuralstem received a Nasdaq deficiency notice on April 20, 2016 because its share price had remained below $1.00 for 30 consecutive business days. It had until October 17, 2016 to regain compliance, subject to potential extensions and possible reverse-stock-split action.
- Key risks include clinical-trial failure or delay, regulatory nonapproval, dependence on third-party manufacturers and clinical research organizations, intellectual-property challenges, substantial debt obligations, dilution from future equity issuance, and the possibility of Nasdaq delisting.
- The former CEO resigned during the quarter. The company entered into a release providing continuing salary, severance payments, healthcare benefits, and immediate vesting of outstanding unvested equity awards.
- No material litigation was identified in the filing, and management reported effective disclosure controls as of March 31, 2016.
Important Facts for Investors to Verify
- Registrant identity: Confirm whether the intended filing was Neuralstem, Inc. rather than Palisade Bio, Inc.
- Subsequent financing: Verify the May 6, 2016 offering, net proceeds, share count, warrant terms, and resulting dilution.
- Liquidity: Reconcile the disclosed June 2016 cash runway with the stated post-financing runway through December 31, 2016.
- Debt maturity and collateral: Review the $435,000 monthly payments, April 2017 balloon payment, covenants, and security interest in intellectual property.
- Going concern: Assess whether additional financing will be required after the May offering and whether the company can fund planned clinical development.
- Clinical execution: Track enrollment and results for the NSI-189 Phase 2 trial and funding or partnership progress for NSI-566.
- Nasdaq compliance: Verify subsequent bid-price compliance, any reverse stock split, extension, appeal, or delisting action.